← Patent-cliff monitor small molecule LIVMARLI MARALIXIBAT CHLORIDE
Loss of exclusivity October 2032 latest FDA-listed patent expiry
Drug detail Brand name LIVMARLI Active ingredient MARALIXIBAT CHLORIDE Strength EQ 19MG BASE/ML Dosage form SOLUTION Route ORAL Modality Small molecule FDA approval July 2024 Marketing status RX
Listed patents Patent Expires Type 12350267 October 2032 use U-3973 11229661 October 2032 use U-3973 10512657 October 2032 use U-3973
Regulatory exclusivity Code Expires ODE-490 July 2031 ODE* March 2031 ODE* March 2030 ODE* September 2028 NCE September 2026
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.